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Abstract. A series of variously substituted furochromenes, hemiacetals 2, acetals 3, and rearranged com-
pounds 4, were synthesized from variously substituted 4-hydroxycoumarins and evaluated in several in 
vitro assays, inhibition of mast cell degranulation induced by the activation of Fcε receptor type I or calci-
um ionophore and leukotriene B4 (LTB4) inhibition. The most active derivatives, 3p and 4p (8-iso-propyl 
substitution in coumarin ring) and 3r (5-methyl-8-chloro substitution), showed significant inhibition of 
mast cell degranulation (Fctriggered) and LTB4, and exhibited significant local anti-inflammatory activ-
ity in PMA induced ear edema in CD1 mice, with potency equal (compounds 3p and 4p) or better (com-
pound 3r) in comparison with zileuton, a reference drug used. It might be a promising direction for devel-
oping novel drugs as potential agents for the treatment of allergies and other inflammatory diseases.(doi: 
10.5562/cca2240) 
Keywords: furochromenes; 4-hydroxycoumarins; mast cell degranulation; leukotriene B4; anti-
inflammatory activity; ear edema 
 
INTRODUCTION 
Coumarins represent an important class of oxygenated 
heterocycles. Since many of them, both naturally occur-
ring and synthetic, possess diverse array of biological 
activities, they are also of potential pharmaceutical 
interest. In nature they act as plant growth regulation 
factors, UV-filters and protectors from sun radiation, or 
as insecticides, antivirals or antibacterial agents.1 
4-Hydroxycoumarin was determined as a building 
unit of natural product dicoumarol, isolated from 
spoiled sweet clover and identified as a causative agent 
of haemorrhagic cattle deaths.2 The intensive investiga-
tions of many natural and synthetic coumarins resulted 
in discovery of warfarin and other 3-alkyl-4-
hydroxycoumarins as potent, clinically used anticoagu-
lants,3–8 mainly used in postsurgical prevention of 
wound induced thrombus formation. Intensive investi-
gation on the molecular level of action of these com-
pounds showed that they prevent reduction of vitamin K 
epoxide to active vitamin K thus inhibiting the biosyn-
thesis of protrombin and other clothing factors.9 
Coumarins belonging to different chemical classes 
have been studied.10 There are evidences of the anti-
retroviral activity of coumarin derivatives and their 
ability to inhibit HIV integrase.11–14 Some 3-aryl and 3-
heteroaryl derivatives are inhibitors of macrophage 
migration inhibitory factor (MIF),15 while natural 
coumarin product cnidicin16 (Figure 1), isolated from 
the root extract of Angelica koreana (Umbelliferae), is 
an active component responsible for the inhibitory ef-
fect on the degranulation process of cultured mast cells. 
Cnidicin demonstrated a significant inhibition upon the 
release of -hexosaminidase from the cultured RBL-
2H3 cells in a dose dependent manner and the IC50 
value was calculated as 25 ± 2.1 M, which is compara-
ble to that of azelastine (26 ± 3.2 M) an anti-allergic 
drug known to inhibit the degranulation of mast cells. 
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This result implied an anti-allergic action of cnidicin in 
vitro. 
Another coumarin compound, selinidin (Figure 
1),17 isolated from the extract of A. keiskei is an 
antiallergic compound in screening employing rat baso-
philic leukemia RBL-2H3 cells. Selinidin had an inhibi-
tory effect on degranulation of RBL-2H3 cells upon 
engagement of Fcε receptor type I with IgE and antigen. 
Furthermore, it was shown that selinidin modulates Fcε 
receptor type I mediated signaling although it does not 
prevent IgE-Fcε receptor type I binding and cell surface 
Fcε receptor type I expression. These results suggest 
that selinidin suppresses IgE-mediated mast cell activa-
tion by inhibiting signal transduction pathways through 
Fcε receptor type I. 
Also, it was documented that some synthetic aryl 
substituted 3-tetrazolylcoumarins,18,19 and 3-nitro-4-
hydroxycoumarins20,21 inhibit degranulation of mast 
cells thus preventing release of chemical mediators such 
as cysteinyl leukotrienes C4, D4 and E4 (originally de-
scribed as slow-reacting substances of anaphylaxis, 
SRS-A) and histamine. In addition, a broad array of 
other therapeutic applications of natural and synthetic 
coumarins has been reported in the literature, especially 
concerning their anti-inflammatory / antioxidant proper-
ties,22–25 their application as neuroprotecting agents,26 as 
well as in pharmacotherapy of breast cancer.27 
Furocoumarins are a class of natural and synthetic 
compounds used as photoreactive, antiviral, anti-
inflammatory agents as well as kinase inhibitors.28 
Furo[4,3-c]coumarins are generally prepared by con-
densation of aryl substituted 4-hydroxycoumarins as 
dinucleophiles and vicinal dielectrophiles.26,29 
In a quest for new anti-inflammatory / antiallergic 
therapeutics we screened our compound collection in 
mast cell degranulation assays and leukotriene B4 assay. 
Here, we wish to present the synthesis of several so far 
unreported classes of coumarin compounds, variously 
substituted furochromenes 2–4, as well as to report the 
results on evaluation of their biological activity. 
Anti-inflammatory activity of prepared com-
pounds was examined on the basis of in vitro tests, 
inhibition of mast cell (RBL-2H3 cell line of rat baso-
philic leukaemia) degranulation induced by the activa-
tion of Fcε receptor type I. There is significant evidence 
that mast cells, basophils, and their released mediators 
are primary effectors of allergic inflammation. Mast 
cells may contribute to the pathophysiology of a wide 
variety of diseases including asthma, cardiomyopathy, 
schleroderma, arthritis, and fibrotic lung disorders. It is 
believed that many of the deleterious effects that mast 
cells mediate are due to a variety of proinflammatory 
molecules exocytosed with exposure to antigen and the 
subsequent crosslinking of cell-surface-bound immuno-
globulin E (IgE), including histamine, serotonin, and the 
proteases tryptase, chymase, and carboxypeptidase. 
Furthermore, mast cell activation results in the release 
and increased production of cytokines including inter-
leukins 4–6, tumor necrosis factor- alpha, prostaglandin 
D2, and leukotrienes A4 and C4. Clearly, modulation of 
mast cell activation and degranulation could significant-
ly affect a number of disease states.30 
The inhibition of degranulation may prevent the 
symptoms and arrest the inflammation progress, which 
has been proven by the clinical use of degranulation 
inhibitors (sodium chromoglycate, nedochromyl sodium 
and ketotifen). Cysteinyl leukotriene antagonists have 
also proven efficacy in asthma therapy.31 Therapeutical-
ly, the 5-lipoxygenase inhibitor, zileuton, is as effective 
as cysteinyl leukotriene antagonists, and its therapeutic 
effects are indistinguishable from those of the cysteinyl 
leukotriene antagonists. Number of LTB4 antagonists 
were reported as well.32 
Discovery of new generation of compounds which 
would inhibit mast cell degranulation as well as prevent 
synthesis of leukotrienes potentially provides a thera-
peutic approach for treatment of allergies and other 
inflammatory diseases. 
Anti-inflammatory potential of selected com-
pounds was also evaluated in the in vivo anti-
inflammatory model of phorbol 12-myristate 13-acetate 
(PMA) induced ear oedema in CD1 mice. Mouse ear 
inflammation induced by different irritants, including 
PMA provides a range of skin inflammation models 





Starting 4-hydroxycoumarins 1a, d, f–h and l were 
commercially available. All other 4-hydroxycouma-
rins 1b–c, e, i–k, m–r were synthesised according to 
protocols described in literature34 and references cit-
Figure 1. Cnidicin (A) and selinidin (B). 
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ied therein. NMR spectra were recorded at 24 °C on a 
Bruker Avance DPX 300 spectrometer. Chemical 
shifts are reported as  (ppm) relative to TMS as in-
ternal standard, and J is in Hz. High performance 
liquid chromatography-mass spectrometry (HPLC-
MS) analysis were performed using a Waters XTerra 
RP18 analytical column (packing: 3.0 × 100 mm) on a 
Quattro micro™ (Micromass) mass spectrometer, 
using external calibration. Gradient was from 20 % 
MeCN / 0.1 % TFA in water to 80 % MeCN / 0.1 % 
TFA (flow rate 0.6 or 1 ml min−1) over 15 min. The 
UV absorption was monitored at 310 nm. Reported 
values are monoisotopic masses. For all synthesized 




General synthetic methodology for Furochromenes 2–4 
General methodology to prepare hemiacetals 2. 
Appropriate 4-hydroxycoumarin 1 (1 mmol) was mixed 
with a 40 % aqueous solution of glyoxal (2.5 mmol). 
Acetonitrile (5–10 ml) was added thereto and the 
reaction mixture was refluxed for 2–6 hours. After 
cooling the product was filtered and washed with 
acetonitrile, affording hydroxy furochromen derivatives 
2a–p as pure compounds. 
General methodology to prepare acetals 3. Into a 
solution of appropriate 4-hydroxycoumarin 1 (1 mmol) 
in MeOH (5 ml) was added aqueous dimethoxya-
cetaldehyde (60 % solution, 8 mmol). Reaction mixture 
was stirred at reflux temperature for 5 hours. After cool-
ing to room temperature, product was collected by fil-
tration and washed with MeOH, affording 3a–r as pure 
compounds. 
General methodology to prepare rearranged com-
pounds 4. Appropriate metoxy furochromen derivative 3 
(0.3 mmol) was suspended in acetic acid (5 ml). The 
reaction mixture was refluxed for 1–24 hours, whereat 
the starting material was dissolved, and then a precipi-
tate was formed. After cooling to the room temperature 
the product was collected by filtration and washed with 
acetic acid and diethyl ether, affording furochromen 
derivatives 4 as pure compounds. 
Synthetic procedure for enol ether 5. To a suspen-
sion of 2a (0.412 mmol) in Me2CO (10 ml) powdered 
anhydrous K2CO3 (2.89 mmol) was added, followed by 
Me2SO4 (2.12 mmol). Reaction mixture was heated to 
reflux and vigorously stirred for 24 hours, cooled to 
room temperature, followed by filtration. The filtrate 
was evaporated to dryness and the residue then triturat-
ed with ice-cold water for 10 minutes, filtered off and 
recrystallized from MeOH (140 mg / 25 ml) to obtain 
product 5. 
Synthetic procedure for acetylation of compound 
3a. A suspension of 3a (1.05 mmol) in Ac2O (12 ml) 
was stirred at reflux for 1 h. After cooling to room tem-
perature, resulting precipitate was collected by filtration, 
washed with CH3CN to afford product 6, which was 
further recrystallized from Ac2O. 
 
2-hydroxy-3-(4-hydroxy-2-oxo-2H-chromene-3-yl)-
2,3-dihydro-4H-furo[3,2c]chromene-4-one (2a). (0.13 
g, 74 %); white solid; 1H-NMR (300 MHz, DMSO-d6) 
 / ppm: 4.84 (s, 1H), 6.29 (bs, 1H), 7.28–7.58 (m, 
4H), 7.63–7.80 (m, 3H), 8.04 (d, J = 7.6 Hz, 1H), 
12.02 (bs, 1H); 13C-NMR (75.4 MHz, DMSO-d6,)  / 
ppm: 43.8, 101.6, 101.9, 109.6, 111.9, 115.8, 116.3, 
116.6, 122.6, 123.3, 123.9, 124.3, 132.3, 132.7, 152, 





4-one (3a). (0.15 g, 80 %); white solid; 1H-NMR (300 
MHz, DMSO-d6)  / ppm: 3.69 (s, 3H), 5.02 (d, J = 2 
Hz, 1H), 6.24 (d, J = 3.5 Hz, 1H), 7.54-7.71 (m, 2H), 
7.90 (s, 1H), 7.98 (s, 1H), 7.99-8.10 (m, 2H), 8.21 (d, J 
= 7.9 Hz, 1H), 8.51 (s, 1H), 8.67 (s, 1H); 13C-NMR 
(75.4 MHz, DMSO-d6,)  / ppm: 42.5, 56.6, 100.8, 
102.1, 111.9, 114.6, 115.8, 116.3, 116.6, 122.6, 123.5, 
124, 124.4, 132.5, 132.9, 152.1, 154.1, 158.2, 161.4, 




c]chromene-4-one (4a). (0.05 g, 45 %); yellow solid; 
1H-NMR (300 MHz, DMSO-d6)  / ppm: 7.28 (s, 1H), 
7.39-7.49 (m, 3H), 7.52-7.79 (m, 3H), 7.96 (dd, J = 7.8 
Hz, J = 1.4 Hz, 1H), 8.09 (dd, J = 8.2 Hz, J = 1.7 Hz, 
1H); 13C-NMR (75 MHz, DMSO-d6)  / ppm: 108.2, 
110, 112, 115.9, 116.2, 116.6, 120.6, 123.7, 123.9, 
124.4, 130.4, 132.8, 149.7, 151.7, 151.9, 152.3, 155.6, 




ethene (5). (0.08 g, 48 %); colorless crystals; 1H-NMR 
(300MHz, CDCl3)  / ppm : 3.85 (s, 3H), 4.05 (s, 3H), 
4.13 (s, 3H), 6.89 (s, 1H), 7.22–7.32 (m, 4H), 7.45–7.52 
(m, 2H), 7.73 (dd, J = 1.5, 7.9 Hz, 1H), 7.83 (dd, J = 
1.5, 7.9 Hz, 1H); 13C-NMR (75 MHz, CDCl3)  / ppm: 
59.8, 60.9, 61, 101.8, 106.9, 113.5, 116.3, 116.5, 118.1, 
118.2, 123.6, 123.7, 123.8, 124, 131.3, 152.2, 152.3, 




methoxy-4H-furo[3,2-c]chromen-4-one (6). (0.38 g, 86 
%); white solid; recrystallization from Ac2O afforded 
colorless crystals; 1H-NMR (300 MHz, DMSO-d6)  / 
ppm : 2.26 (2, 3H), 3.69 (s, 3H), 5.02 (d, J = 2 Hz, 1H), 
6.24 (d, J = 3.5 Hz, 1H), 7.61-7.75 (m, 2H), 7.90 (s, 
1H), 7.98 (s, 1H), 7.89-8.13 (m, 2H), 8.21 (d, J = 7.9 
Hz, 1H), 8.51 (s, 1H), 8.67 (s, 1H); ES-MS m / z: 421.3 
[M-H]−. 
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X-Ray Crystallography 
Crystal structures of compounds 5 and 6 were deter-
mined by the single crystal X-ray diffraction method. 
Data were collected at 100 K with a Kappa-CCD Nono-
ius diffractometer using graphite monochromated CuK 
radiation. Data reduction was carried out using DENZO 
and SCALEPACK35 software. The details of crystal da-
ta collection and refinement parameters for compounds 
5 and 6 are listed in Table 1. Further details on crystal 
structure investigation are available free of charge on 
application to CCDC, 12 Union Road, Cambridge CB2 
IEZ, UK, www.ccdc.ac.uk/conts/retrieving.html or 
deposit@ccdc.cam.ac.uk under following deposition 
numbers; CCDC 941948 for compound 5 and CCDC 
941949 for compound 6. 
The structure was solved by direct methods imple-
ment in SHELXS9736 and refined by a full-matrix least-
squares method based on F2 using SHELXL97.35 Hydro-
gen atoms were positioned geometrically at calculated 
positions and allowed to ride on their parent atoms. 
 
Computational Studies 
Geometry optimization of examined compounds was 
performed using the density functional theory (DFT) at 
B3LYP37,38 level with 6-31G(d,p) basis set. Zero-point 
vibration energy (ZPVE) correction with scaling factor 
Table 1. Crystal data and structure refinement for compounds 5 and 6 
Compound 5 6 
Empirical formula C23H18O7 C23H16O8 
Formula weight 406.37 420.36 
Temperature (K) 100(2) 100 
Wavelength (Å) 1.54178 1.54178 
Crystal system monoclinic monoclinic 
Space group P21/c P21/n 
Unit cell dimensions  a = 14.0614(5) Å a = 9.5110(3) Å 
b = 8.3013(4) Å b = 16.5891(6) Å 
c = 17.9313(5) Å c = 12.6032(6) Å 
 =  = 90°  =  = 90° 
 = 112.060(5)°  = 111.200(11)° 
Volume (Å3) 1939.85(15) 1853.9(2) 
Z 4 4 
Calculated density (Mg m−3) 1.391  1.506 
Absorption coefficient (mm−1) 0.868  0.115 
F(000) 848 872 
Crystal size (mm) 0.4 × 0.2 × 0.2 0.3 × 0.3 × 0.2 
Limiting indices -16 ≤ h ≤ 16 -11 ≤ h ≤ 11 
Limiting indices  -9 ≤ k ≤ 9 -19 ≤ k ≤ 19 
Limiting indices -21 ≤ l ≤ 20 -14 ≤ l ≤ 14 
Reflections collected / unique 5638 / 3284 [R(int) = 0.1009] 5834 / 3098 [R(int) = 0.0474] 
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on F2 
Data / restraints / parameters 3284 / 0 / 271 3098 / 0 / 281 
Goodness-of-fit on F2 1.027 0.981 
Final R1 / wR2 [I > 2(I)] 0.0685 / 0.1921 0.0529 / 0.1325 
R1 / wR2 (all data) 0.0818 / 0.2102 0.0833 / 0.1517 
Largest diff. peak / hole (e Å−3) 0.310 / -0.233 0.459 / -0.503 
Extinction coefficient - 0.036(5) 
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of 0.960839 was applied. Computations and visualiza-
tions were performed using Jaguar40 and Maestro41 
programs, respectively, from the Schrödinger Suite 
2011. 
 
Inhibition of RBL-2H3 Mast Cell Degranulation 
RBL-2H3 cell line of rat basophilic leukaemia (from 
ATCC) was used for the investigation of inhibition of 
degranulation induced by the activation of Fcε receptor 
type I or calcium ionophors. RBL-2H3 cell line was 
cultivated in DMEM medium (Invitrogen Corporation 
Cat. No. 31966-021) with 10 % of phoetal calf serum 
(Invitrogen Corporation) at 37 °C, 5 % CO2, 90 % rela-
tive humidity. Cells were seeded in the same medium 
into 24-well plates, 50000 per well, and left to reach 80–
90 % of confluence. 
Dilutions of compounds were prepared in DMEM 
medium without phenol red (Invitrogen Corporation) in 
concentrations from 200 μM to 1 μM. The medium was 
removed from the cells and the diluted of compounds 
were added to the wells with the exception of the posi-
tive and the negative control where pure DMEM medi-
um was added. Subsequently, 
1. for the IgE-induced degranulation by Fcε re-
ceptor type I, a solution of SPE-1 
(dinitrophenyl specific IgE) antibodies (Sigma) 
and dinitrophenylalbumin (Sigma), both in a 
final concentration of 0.5 g ml−1, 
2. for Ca2+-induced degranulation by means of a 
calcium ionophore, the solution A23187 
(Calbiochem) in a final concentration of 250 ng 
ml−1, were added to the wells. 
In the case of the negative control wells, pure 
DMEM medium was added. The cells were incubated 
for one hour at 37 °C, 5 % CO2, and 90 % relative hu-
midity. Each dilution as well as the positive and the 
negative controls were performed in triplicate. 
The supernatant (50 μl) was transferred in duplicate 
to a 96-well plate. Thereto 100 μl of 50 mM sodium 
citrate buffer with 1 mg ml-1 para-nitrophenyl-N-acetyl-β-
D-glucosaminide (Calbiochem) were added and it was 
incubated for 1 hour at 37 °C. The reaction was stopped 
with 100 μl of a saturated sodium carbonate solution. The 
absorbance was measured at 405 nm. The percentage of 
inhibition was expressed by the formula: 
% inhibition = (1-(OD405sample - OD405negative 
control) / (OD405positive control - OD405negative con-
trol)) × 100. 
Ketotifen, used as a standard, significantly inhibits 
degranulation in concentrations from 200-50 M. 
 
Leukotriene B4 (LTB4) Inhibition Assay 
Compounds were assayed for their ability to inhibit the 
production of leukotriene B4 in A23187 stimulated 
RBL-2H3 cells. RBL-2H3 cell line (ATCC 2256) is 
grown in DMEM medium (Invitrogen) supplemented 
with 10 % FBS (Invitrogen) in the atmosphere of 5 % 
CO2, 90 % humidity, 37 °C. Cells are trypsinazed, 
washed with fresh DMEM medium and adjusted to 1 × 
105 cells / ml. 500 l / well of cell suspension is trans-
ferred into 24 well plate (Falcon) and grown overnight 
in culturing condition described herein. 10 mM solu-
tions of tested compounds are prepared in DMSO (Sig-
ma), and dissolved in working concentrations in DMEM 
medium without phenol red (Invitrogen). Dilutions of 
tested compounds are placed on cells, whereas for posi-
tive and negative controls only DMEM medium without 
phenol red are used and left in culturing conditions for 
30 minutes. A23187 (Sigma) was added into all wells 
except negative controls in the final concentration of 
250 nM and left for 45 minutes in culturing conditions. 
10 l of cellular supernatant was used to determine 
leukotriene B4 levels using ELISA (R&D systems). 
Total concentrations of LTB4 are calculated in samples 
and total inhibition was calculated using the formula: 
% inhibition = (1 - LTB4 sample concentration / 
LTB4 positive control concentration) × 100. 
 
Phorbol 12-myristate 13-acetate (PMA) Induced Ear 
Oedema in CD1 Mice 
Male CD1 mice (Iffa Credo, France) weighing ≈ 35–40 
g were randomly grouped (n = 8 in vehicle treated test 
group, dexamethasone treated control group as well as 
in groups treated with compounds to be assayed). Test 
compounds, dexamethasone as well as vehicle (Trans-
phase Delivery System, containing benzyl alcohol 10 %, 
acetone 40 % and isopropanol 50 %) (all from Kemika, 
Croatia), were administered topically to the internal 
surface of the left ear thirty minutes prior to administra-
tion of phorbol 12-myristate 13-acetate (PMA) (Alexis 
biochemicals, USA). Test compounds were adminis-
tered at a single dose of 250 or 100 g / 15 µl / ear and 
dexamethasone at a single dose of 50 g / 15 µl / ear. 
Thirty minutes later, 0.01 % PMA solution in acetone 
was applied topically to the same area of each animal in 
a volume of 12 µl / ear. During the treatment and chal-
lenge, animals were anaesthetized by using inhalation 
anaesthesia. Six hours after the challenge, animals were 
euthanized by asphyxiation in 100 % CO2 atmosphere. 
For assessing the auricular oedema, 8 mm discs were 
cut out of left and right auricular pinna and weighed. 
The degree of oedema was calculated by subtracting the 
weight of 8 mm disc of the untreated ear from that of 
the treated contralateral ear. 
The compound at appropriate dose is considered 
active if the supression of ear oedema in compound 
treated group is statistically significantly different in 
comparison to positive control group, as calculated by 
the non-parametric ANOVA statistical method (statisti-
cal analysis was done using the program GraphPad 
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Statement. All procedures on animals were per-
formed in accordance with (a) the EEC Council Di-
rective 86 / 609 of 24th November 1986 on the approx-
imation of laws, regulations and administrative provi-
sions of the Member States regarding the protection of 
animals used for experimental and other scientific pur-
poses; and (b) Statute of Republic Croatia, Animal Wel-
fare Law, NN 135 of 13th December 2006. 
 
RESULTS AND DISCUSSION 
Chemistry 
The compounds under study were prepared by conden-
sation reaction of variously substituted hydroxycouma-
rins with glyoxal or dimethoxyacetaldehyde as dielec-
trophiles via tandem Knöevenagel / Michael addition 
reaction, followed by annulation and dihydrofuran ring 
formation (Scheme 1). When reaction was performed in 
nonnucleophilic solvent, such as acetonitrile, hemia-
cetals 2 were isolated as final products while acetals 3 
were isolated after condensation in alcoholic solvent, 
e.g. methanol (as exemplified in this paper) or ethanol 
(not shown). Treatment of either 2 or 3 with dehydrating 
agents such as acetic acid or trifluoroacetic acid (TFA) 
resulted in the formation of new class of 2-substituted 
furo[3,2-c]chromens 4. In this case elimination of C-2 
substituent is accompanied by rearrangement and migra-
tion of the second coumarin moiety to C-2 position via 
neighbouring participation of 3’-4’ double bond and 
formation of spiro[chroman-cycopropane]dione inter-
mediate. 2-Methyl-4H-furo[3,2-c]chromen-4-one is 
already reported as a product of such rearrangement.42 
 
Scheme 1. Synthesis of furochromen compounds 2-4. Reagents and conditions: a) glyoxal, MeCN, reflux; b) glyoxal, MeOH,
reflux; c) dimethoxyacetaldehyde, MeOH, reflux; d) AcOH or TFA, reflux. 
 
Scheme 2. Cyclic (2a-A) and open chain (2a-B) isomeric forms of 2 and product of methylation (5). 
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Keto-enol tautomerism is the most common struc-
tural isomerism in 4-hydroxycoumarins. Due to dynam-
ic equilibrium tautomers are rapidly interconvertible 
from one isomeric form to another and tautomer deter-
mination is quite challenging.43 Other structural isomers 
are possible as well. In our studies we noticed that in 
compounds 2 ring-chain tautomerism44 also exists 
(Scheme 2). Which of the isomeric form prevails in the 
mixture, cyclic (hemiacetal) or open chain (aldehyde), 
depends on the nature and number of the aromatic sub-
stituents, whether the compound is in a free acid form or 
as a salt. Type of the salt, type of the solvent in which 
the compound is dissolved, as well as the pH value of 
the solution also have an effect on the tautomer ratio. 
For the purpose of structure elucidation NMR 
spectra of investigated compounds were run in DMSO-
d6. The cyclic form (i.e. 2a-A) prevails in such solutions 
with anomeric proton (H-2) at ppm 6.2 and H-3 at 4.8. 
Existence of open chain form was confirmed by stand-
ard methylation reaction with dimethyl sulphate in the 
presence of potassium carbonate. Enol ether 5 was iso-
lated as the only reaction product (Scheme 2). The mo-
lecular and crystal structures of 5 were determined by 
single-crystal X-ray diffraction (Figure 2, Table 1). 
Both series of compounds 2 and 3 contain two 
stereocenters and therefore 4 possible stereoisomers 
could be expected. However, the pair of enantiomers 
with trans- configuration around C2-C3 bond in 3 is 
calculated to be more favorable (Figure 3), which was 
determined experimentally as well. 
Acetylation of 3a afforded compound 6 (Scheme 
3), whose molecular and crystal structures (Figure 4) 
were determined by single-crystal X-ray diffraction 
(Table 1) and product was shown to be a racemic mix-
ture with trans configuration around C2-C3 bond, sug-
gesting (trans)-diastereoselectivity in the formation of 
acetal 3a. 
Figure 2. The molecular structure of compound 5. 
Figure 3. Trans-3a recognized as favored product over cis-3a. 
 





cis-(R,S)-3a [(S,R)-3] trans-(R,R)-3a [(S,S)-3] 
E0(cis-trans) = 6.1 kcal mol-1
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Pharmacology 
The synthesized compounds were evaluated for their 
anti-inflammatory activity in the in vitro RBL-2H3 rat 
mast cells degranulation which was Fcreceptor or 
Ca2+-triggered, and by inhibition of leukotriene B4 
(LTB4)at inhibitor concentration of 10 M.45 For most 
of them Fc receptor triggered degranulation were re-
peated with inhibitor concentration of 30 M indicating 
dose-response behavior of analyzed compounds. Results 
are summarized in Tables 2–4. Compounds that signifi-
cantly inhibited (i.e. 50 % or higher) degranulation of 
mast cells or LTB4 are considered to be fully “active” 
and to possess anti-inflammatory activity. 
The central role of the mast cell in the initiation of 
allergic responses makes it an ideal target for anti-
allergic drug therapy. Mast cells are the primary initiat-
ing cells of immediate hypersensitivity reactions so their 
degranualtion is indicated as invoked in immediate or 
delayed type hypersensitivity reaction, allergy, anaphy-
laxis, inflammation, asthma and urticaria.46 Immunolog-
ical activation of mast cells results not only in degranu-
lation but also in the liberation of arachidonic acid from 
phospholipids in the cell membrane. Their further 
Figure 4. The molecular structure of compound 6. 
Table 2. Inhibition (%) of Fcε receptor triggered (Fcε) and Ca2+-induced (Ca2+) degranulations as well as leukotriene B4 (LTB4) 
production in RBL-2H3 rat mast cells for hemiacetales 2a–2p at an inhibitor concentration of 10 M 
     Fc  Ca2+ LTB4 
Cpd R1 R2 R3 R4 10 M 30 M(a) 10 M 10 M 
2a H H H H   0 ND(b)   0     0 
2b H OH H H   0 ND(b)   0     0 
2c H OMe H H   0 ND(b)   2   23 
2d H Cl H H 64 83   0     0 
2e H H Cl H 75 87 13   13 
2f H Me H H   0 ND(b)   0   18 
2g H H Me H 15 35   0   34 
2h H Me Me H 50 95 23 100 
2i Me H H Me 90 95 22 100 
2j Me H Me H 67 92 50 100 
2k H Me H Me 50 95 12   39 
2l H Cl Me H 50 90 18   33 
2m H Et H H 30 90 11 100 
2n H H H Et 64 93 10   68 
2o H i-Pr H H 70 80   0 100 
2p H H H i-Pr 80 91   5 100 
Dicoumarol     45 45 13     0 
Ketotifen       0 30 ND(b) ND(b) 
Zileuton     22 28   0 100 
(a) Inhibitor concentration of 30 M. (b) ND = not determined.  
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metabolism may proceed along either of two independ-
ent pathways, the cyclooxygenase pathway toward pros-
taglandins and the lypoxygenase pathway which has the 
capacity to generate a wide variety of leukotriene prod-
ucts. Leukotrienes are important mediators in host de-
fense mechanisms and in inflammatory disease states 
due, for example, to their effects on cell migration, 
muscle contraction, vascular permeability, and the re-
lease of lysozomal enzymes.47 
It was observed that majority of studied com-
pounds inhibit mast cells degranulation triggered by Fc 
receptorand only few of them inhibit degranulation 
triggered by Ca2+. Significant inhibition of mast cell 
degranulation induced by the activation of Fcε receptor 
type I showed certain derivatives with alkyl and halogen 
substituents as well as combinations of those substitu-
ents, whereas unsubstituted compounds and those with 
hydroxy and methoxy substituents gave the poorest 
inhibitions. Further, hemiacetals 2 proved to be the most 
active ones, regarding the in vitro activity, but during 
evaluation were proven to be chemically unstable and 
because of that were not fully investigated.48 Acetals 3 
and rearranged compounds 4 are equally potent inhibi-
tors of mast cell (RBL-2H3) degranulation 
(Fctriggered). 
The most potent inhibitors of Fctriggered mast 
cell degranulation bear liphophilic substituent at R4 
position. The potency of derivatives at R4 follows the 
tendency of 2–4p (isopropyl) > 2–4n (ethyl). Methyl at 
R4 is well tolerated in combination with additional me-
thyl group at R1 position as in 2–4i. Introduction of 
lipophilic substituent at R3 position, like chlorine in 2–
4e and methyl in 2g and 4g has positive effect on 
Fctriggered inhibition of mast cell degranulation, 
especially in combination with additional substitution 
with methyl at R1 as in compounds 2–4j. However, R1 / 
R3 combination in 2–4j was somewhat less potent than 
R1 / R4 in 2–4i. Finally, R2 position tolerates only lipo-
philic substituents, and the inhibitory potency of deriva-
tives followed the tendency of 2–4o (isopropyl) > 2–4d 
(chlorine) > 2–4m (ethyl). Less lipophilic or polar 
groups like methyl (2–4f), hydroxy (2–4b), methoxy (2–
Table 3. Inhibition (%) of Fcε receptor triggered (Fcε) and Ca2+-induced (Ca2+) degranulations as well as leukotriene B4 (LTB4) 
production in RBL-2H3 rat mast cells for acetals 3a–3r at an inhibitor concentration of 10 M 
     Fc  Ca2+ LTB4 
Cpd R1 R2 R3 R4 10 M 30 M(a) 10 M 10 M 
3a H H H H   0 ND(b)   0   0 
3b H OH H H   0 ND(b)   0   0 
3c H OMe H H   0 ND(b)   5   0 
3d H Cl H H 30 50 14   0 
3e H H Cl H 39 74 13   0 
3f H Me H H 26 33   0   0 
3g H H Me H ND(b) ND(b) ND(b) ND(b) 
3h H Me Me H 46 51 18 31 
3i Me H H Me 62 92   0   0 
3j Me H Me H 65 96 10   0 
3k H Me H Me 45 50   3   3 
3l H Cl Me H 58 91   0   7 
3m H Et H H 58 80   2   0 
3n H H H Et 69 94 10   0 
3o H i-Pr H H ND(b) ND(b) 10 67 
3p H H H i-Pr 56 89 18 100 
3r Me H H Cl 96 91 26 97 
(a) Inhibitor concentration of 30 M. (b) ND = not determined.  
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4c), were not tolerated and led to almost complete loss 
of activity. Introduction of additional methyl group at 
R3 position increase activity, and generally it was de-
termined that disubstituted R2 / R3 (2–4h and 2–4l) 
derivatives were more potent that monosubstituted R2 
analogues (2–4f and 2–4d, respectively). On the other 
hand, influence of substitutions on LTB4 inhibition 
among three classes is not equivocal. Mostly, substitu-
tions with positive effect on Fctriggered inhibition of 
mast cell degranulation also produce significant LTB4 
inhibition. This trend correlates in series 2 and 4, but 
regarding series 3, most of the substitutions at R1, R2 
and R3 led to complete loss in LTB4 inhibition. Excep-
tions are most lipophilic substituents like isopropyl at R2 
in 3o and at R4 in 3p. Also combination of methyl at R1 
and chlorine at R4 in series 3, led to very potent com-
pound 3r. 
The most promising compounds were then select-
ed for further evaluation in the in vivo anti-
inflammatory model of phorbol 12-myristate 13-acetate 
(PMA) induced ear oedema in CD1 mice (Table 5). 
PMA induction of acute skin inflammation was con-
ducted according to Napoletano et al.49 with some modi-
fications. PMA is tumor-promoting agent, and protein 
kinase C activator widely used to induce cutaneous 
inflammation in experimental animal models. 
Table 4. Inhibition (%) of Fc receptor triggered (Fc) and Ca2+-induced (Ca2+) degranulations as well as leukotriene B4 (LTB4) 
production in RBL-2H3 rat mast cells for 2-substituted furo[3,2]coumarins 4a–4p at an inhibitor concentration of 10  
     Fc  Ca2+ LTB4 
Cpd R1 R2 R3 R4 10 M 30 M(a) 10 M 10 M 
4a H H H H   0 ND(b)   0   0 
4b H OH H H   0 ND(b) 15   0 
4c H OMe H H   0 ND(b)   0   0 
4d H Cl H H   0 ND(b)   2 24 
4e H H Cl H 78 87 18 32 
4f H Me H H   0 ND(b)   6   0 
4g H H Me H 40 40 19 40 
4h H Me Me H 32 ND(b)   0   0 
4i Me H H Me 55 78   6 41 
4j Me H Me H 35 65   0 29 
4k H Me H Me 26 30 24   6 
4l H Cl Me H 68 80 15 31 
4m H Et H H ND(b) ND(b)   1 46 
4n H H H Et 68 71 59 32 
4o H i-Pr H H 59 64 14 100 
4p H H H i-Pr 79 90 37 97 
(a) Inhibitor concentration of 30 M. (b) ND = not determined.  
 
Table 5. In vivo anti-inflammatory activity of selected com-
pounds in the model of phorbol 12-myristate 13-acetate 
(PMA) induced ear oedema in CD1 mice 
  Ear oedema 
Cpd μg / ear % inhibition* 
3p 250 71 
3p 100 39 
3r 100 68 
4p 100 33 
Zileuton 100 38 
Dexamethasone 50 89 
*P < 0.05, Non-parametric ANOVA for all compounds 
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Epicutaneous application of PMA results in vascular 
leakage, leukocyte infiltration, epidermal hyperplasia, 
activation of protein kinase C and increased release of 
arachidonic acid (AA) and its metabolites.50 The initia-
tion of inflammatory responses by metabolites of AA 
and suppression of acute inflammatory responses by 
inhibitors of cyclooxygenase (COX) and lypoxygenase 
(LOX) establish an important role for metabolites of AA 
in acute inflammation induced by AA and PMA.51 
Compounds 3r, 3p and 4p showed statistically 
significant suppression of ear eodema in comparison to 
positive control group, with comparable or even better 
activity to 5-LO and LTB4 inhibitor zileuton. 
These findings attracted us to extend our research 
to this class of compounds in the quest for anti-
inflammatory – antiallergic medication. 
 
CONCLUSION 
Several new series of coumarin compounds, hemiacetals 
2, acetals 3, and rearranged compounds 4, have been 
synthesized and their inhibitory potential to prevent mast 
cell degranulation as well as LTB4 production was evalu-
ated. Significant inhibition of mast cell degranulation 
induced by the activation of Fcε receptor type I showed 
certain derivatives with alkyl and halogen substituents as 
well as combinations of those substituents, whereas 
unsubstituted compounds and those with hydroxy and 
methoxy substituents gave the poorest inhibitions. 
Position R1 is tolerated for Me substituent like in 
2i and 3r. Majority of the active compounds are 
unsubstituted on position R2, however, some com-
pounds with R2 = iPr or Cl shown inhibition larger than 
50 % (2d, 2o, 4o, 3l, 4l). On the other hand, compounds 
with oxygen in R2 (R2 = OH and OMe) haven’t shown 
any activity. Compounds 2e and 4e where R3 = Cl 
shown inhibitor activity larger than 75 %. Position R4 is 
tolerated for larger lipophilic substituents like Et (2n, 
3n, 4n) and iPr (2p, 4p). Additionally, in combination 
with R2 = Me, compounds where R4 = Cl (3r) and Me 
(2i, 3i, 4i) shown the best activities in this set. 
Significant inhibition of LTB4 exhibited mono- 
and bi-alkyl substituted compounds 2h–j, 2m–p, 3o–p, 
and 4o–p as well as 5-methyl-8-chloro substituted de-
rivative 3r. 
Selected compounds, 3p, 4p and 3r, exhibited sig-
nificant anti-inflammatory activity in PMA induced ear 
edema in CD1 mice, with potency equal (compounds 3p 
and 4p) or better (compound 3r) in comparison with 
zileuton as the reference compound. This is very signif-
icant finding since it opens a new possibility of develop-
ing new class of non-steroidal compounds for the treat-
ment of inflammatory diseases. 
Further structural modifications are in progress 
with a view to shedding light on the better understand-
ing of anti-inflammatory activity of 4-hydroxycoumarin 




RBL-2H3 – Cell line of rat basophilic leukaemia 
LTB4 – Leukotriene B4 
IgE – Immunoglobulin E 
Fcε receptors – Fc receptors that bind IgE 
PMA – Phorbol 12-myristate 13-acetate 
DMEM – Dulbecco's modification of Eagle's medium 
FBS – Fetal bovine serum 
ELISA – Enzyme-linked immunosorbent assay 
ANOVA – Analysis-of-variance statistical test 
Supplementary Materials. – Supporting informations to the 
paper are enclosed to the electronic version of the article. 
These data can be found on the website of Croatica Chemica 
Acta (http://public.carnet.hr/ccacaa). 
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